 | • レポートコード：MRC2-11QY04206 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はペプチド感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（テラプレビル、ソフォスブビル、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ペプチド感染症治療薬の競争状況、市場シェア ・世界のペプチド感染症治療薬市場：種類別市場規模 2015年-2020年（テラプレビル、ソフォスブビル、その他） ・世界のペプチド感染症治療薬市場：種類別市場規模予測 2021年-2026年（テラプレビル、ソフォスブビル、その他） ・世界のペプチド感染症治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界のペプチド感染症治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米のペプチド感染症治療薬市場分析：米国、カナダ ・ヨーロッパのペプチド感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのペプチド感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のペプチド感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのペプチド感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Gilead Sciences、Johnson & Johnson (Janssen)、Vertex Pharmaceuticals、Mitsubishi Tanabe Pharma、Medivir ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective.
Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market.
Market Analysis and Insights: Global Peptide Based Infection Therapeutics Market
The global Peptide Based Infection Therapeutics market size is projected to reach US$ 24200 million by 2026, from US$ 22880 million in 2020, at a CAGR of 5.3%% during 2021-2026.
Global Peptide Based Infection Therapeutics Scope and Market Size
Peptide Based Infection Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peptide Based Infection Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Gilead Sciences
Johnson & Johnson (Janssen)
Vertex Pharmaceuticals
Mitsubishi Tanabe Pharma
Medivir
…
Market segment by Type, the product can be split into
Telaprevir
Sofosbuvir
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Peptide Based Infection Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Telaprevir
1.4.3 Sofosbuvir
1.4.4 Others
1.5 Market by Application
1.5.1 Global Peptide Based Infection Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Peptide Based Infection Therapeutics Market Perspective (2015-2026)
2.2 Global Peptide Based Infection Therapeutics Growth Trends by Regions
2.2.1 Peptide Based Infection Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Peptide Based Infection Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Peptide Based Infection Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Peptide Based Infection Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Peptide Based Infection Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Peptide Based Infection Therapeutics Players by Market Size
3.1.1 Global Top Peptide Based Infection Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Peptide Based Infection Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Peptide Based Infection Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Peptide Based Infection Therapeutics Market Concentration Ratio
3.2.1 Global Peptide Based Infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Peptide Based Infection Therapeutics Revenue in 2019
3.3 Peptide Based Infection Therapeutics Key Players Head office and Area Served
3.4 Key Players Peptide Based Infection Therapeutics Product Solution and Service
3.5 Date of Enter into Peptide Based Infection Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Peptide Based Infection Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
5.2 Global Peptide Based Infection Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Peptide Based Infection Therapeutics Market Size (2015-2020)
6.2 Peptide Based Infection Therapeutics Key Players in North America (2019-2020)
6.3 North America Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
6.4 North America Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Peptide Based Infection Therapeutics Market Size (2015-2020)
7.2 Peptide Based Infection Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
7.4 Europe Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Peptide Based Infection Therapeutics Market Size (2015-2020)
8.2 Peptide Based Infection Therapeutics Key Players in China (2019-2020)
8.3 China Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
8.4 China Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Peptide Based Infection Therapeutics Market Size (2015-2020)
9.2 Peptide Based Infection Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
9.4 Japan Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Peptide Based Infection Therapeutics Market Size (2015-2020)
10.2 Peptide Based Infection Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Peptide Based Infection Therapeutics Market Size (2015-2020)
11.2 Peptide Based Infection Therapeutics Key Players in India (2019-2020)
11.3 India Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
11.4 India Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Peptide Based Infection Therapeutics Market Size (2015-2020)
12.2 Peptide Based Infection Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Peptide Based Infection Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Peptide Based Infection Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Gilead Sciences
13.1.1 Gilead Sciences Company Details
13.1.2 Gilead Sciences Business Overview
13.1.3 Gilead Sciences Peptide Based Infection Therapeutics Introduction
13.1.4 Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2015-2020))
13.1.5 Gilead Sciences Recent Development
13.2 Johnson & Johnson (Janssen)
13.2.1 Johnson & Johnson (Janssen) Company Details
13.2.2 Johnson & Johnson (Janssen) Business Overview
13.2.3 Johnson & Johnson (Janssen) Peptide Based Infection Therapeutics Introduction
13.2.4 Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2015-2020)
13.2.5 Johnson & Johnson (Janssen) Recent Development
13.3 Vertex Pharmaceuticals
13.3.1 Vertex Pharmaceuticals Company Details
13.3.2 Vertex Pharmaceuticals Business Overview
13.3.3 Vertex Pharmaceuticals Peptide Based Infection Therapeutics Introduction
13.3.4 Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2015-2020)
13.3.5 Vertex Pharmaceuticals Recent Development
13.4 Mitsubishi Tanabe Pharma
13.4.1 Mitsubishi Tanabe Pharma Company Details
13.4.2 Mitsubishi Tanabe Pharma Business Overview
13.4.3 Mitsubishi Tanabe Pharma Peptide Based Infection Therapeutics Introduction
13.4.4 Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2015-2020)
13.4.5 Mitsubishi Tanabe Pharma Recent Development
13.5 Medivir
13.5.1 Medivir Company Details
13.5.2 Medivir Business Overview
13.5.3 Medivir Peptide Based Infection Therapeutics Introduction
13.5.4 Medivir Revenue in Peptide Based Infection Therapeutics Business (2015-2020)
13.5.5 Medivir Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Peptide Based Infection Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Peptide Based Infection Therapeutics Revenue
Table 3. Ranking of Global Top Peptide Based Infection Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Peptide Based Infection Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Telaprevir
Table 6. Key Players of Sofosbuvir
Table 7. Key Players of Others
Table 8. Global Peptide Based Infection Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Peptide Based Infection Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Peptide Based Infection Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Peptide Based Infection Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Peptide Based Infection Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Peptide Based Infection Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Peptide Based Infection Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Peptide Based Infection Therapeutics Players
Table 19. Global Peptide Based Infection Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Peptide Based Infection Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Infection Therapeutics as of 2019)
Table 22. Global Peptide Based Infection Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Peptide Based Infection Therapeutics Product Solution and Service
Table 25. Date of Enter into Peptide Based Infection Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Peptide Based Infection Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Peptide Based Infection Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Peptide Based Infection Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Peptide Based Infection Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 35. North America Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 37. North America Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 41. Europe Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 47. China Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 49. China Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 53. Japan Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 65. India Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 67. India Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Peptide Based Infection Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Peptide Based Infection Therapeutics Market Share (2019-2020)
Table 71. Central & South America Peptide Based Infection Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Peptide Based Infection Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Peptide Based Infection Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Peptide Based Infection Therapeutics Market Share by Application (2015-2020)
Table 75. Gilead Sciences Company Details
Table 76. Gilead Sciences Business Overview
Table 77. Gilead Sciences Product
Table 78. Gilead Sciences Revenue in Peptide Based Infection Therapeutics Business (2015-2020) (Million US$)
Table 79. Gilead Sciences Recent Development
Table 80. Johnson & Johnson (Janssen) Company Details
Table 81. Johnson & Johnson (Janssen) Business Overview
Table 82. Johnson & Johnson (Janssen) Product
Table 83. Johnson & Johnson (Janssen) Revenue in Peptide Based Infection Therapeutics Business (2015-2020) (Million US$)
Table 84. Johnson & Johnson (Janssen) Recent Development
Table 85. Vertex Pharmaceuticals Company Details
Table 86. Vertex Pharmaceuticals Business Overview
Table 87. Vertex Pharmaceuticals Product
Table 88. Vertex Pharmaceuticals Revenue in Peptide Based Infection Therapeutics Business (2015-2020) (Million US$)
Table 89. Vertex Pharmaceuticals Recent Development
Table 90. Mitsubishi Tanabe Pharma Company Details
Table 91. Mitsubishi Tanabe Pharma Business Overview
Table 92. Mitsubishi Tanabe Pharma Product
Table 93. Mitsubishi Tanabe Pharma Revenue in Peptide Based Infection Therapeutics Business (2015-2020) (Million US$)
Table 94. Mitsubishi Tanabe Pharma Recent Development
Table 95. Medivir Company Details
Table 96. Medivir Business Overview
Table 97. Medivir Product
Table 98. Medivir Revenue in Peptide Based Infection Therapeutics Business (2015-2020) (Million US$)
Table 99. Medivir Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peptide Based Infection Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Telaprevir Features
Figure 3. Sofosbuvir Features
Figure 4. Others Features
Figure 5. Global Peptide Based Infection Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Peptide Based Infection Therapeutics Report Years Considered
Figure 10. Global Peptide Based Infection Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Peptide Based Infection Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Peptide Based Infection Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Peptide Based Infection Therapeutics Market Share by Players in 2019
Figure 15. Global Top Peptide Based Infection Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Based Infection Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Peptide Based Infection Therapeutics Revenue in 2019
Figure 17. North America Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Peptide Based Infection Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
ペプチド胃腸障害治療薬の世界市場（～2026年） Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas. Market Analysis and Insights: Global Peptide Based Gastrointesti…- ペプチド癌治療薬の世界市場（～2026年） Peptide is a compound that is created by artificial or natural biological chaining of amino acid monomers. In recent years, peptides have emerged as an effective therapeutic agent in treatment of various diseases, including cancer. Market Analysis and Insights: Global Peptide Based Cancer Therapeuti…
- ペプチド心血管治療薬の世界市場（～2026年） Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Other CVDs include stroke, heart failure, hypertensive heart diseas…
- ペプチド代謝障害治療薬の世界市場（～2026年） A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, effici…
- クラミジア感染症診断・治療の世界市場（～2026年） The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities. Market Analysis and Insights: Global Chlamydia Infection Diagnostics and Therapeutics Market The global Chlamydia Infection Diagnostics and The…